A REVIEW ON CUBOSOMES FOR TARGETED THERAPY IN TRIPLE-NEGATIVE BREAST CANCER AND OPTIMIZING THROUGH QBD

Triple-Negative Breast Cancer, commonly abbreviated as TNBC, is a distinctive form of breast cancer that lacks three critical receptors: estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2) as shown in Fig 1. These receptors are typically involved in the growth and spread of most breast cancers, and their absence in TNBC means that common hormonal and targeted therapies are ineffective. TNBC.[1-3] represents roughly 10% to 20% of all breast cancer diagnoses and is known for its particular aggressiveness and tendency to affect younger women compared to other breast cancer types.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-09-01
DOI
https://doi.org/10.5281/zenodo.22159644
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A REVIEW ON CUBOSOMES FOR TARGETED THERAPY IN TRIPLE-NEGATIVE BREAST CANCER AND OPTIMIZING THROUGH QBD

Prof. Kumaraswamy Gandla2* Muzahidul Islam Akanda1
Zenodo (CERN European Organization for Nuclear Research)
Breast Cancer Treatment Studies
article

A REVIEW ON CUBOSOMES FOR TARGETED THERAPY IN TRIPLE-NEGATIVE BREAST CANCER AND OPTIMIZING THROUGH QBD

Prof. Kumaraswamy Gandla2* Muzahidul Islam Akanda1
article en

Abstract

Triple-Negative Breast Cancer, commonly abbreviated as TNBC, is a distinctive form of breast cancer that lacks three critical receptors: estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2) as shown in Fig 1. These receptors are typically involved in the growth and spread of most breast cancers, and their absence in TNBC means that common hormonal and targeted therapies are ineffective. TNBC.[1-3] represents roughly 10% to 20% of all breast cancer diagnoses and is known for its particular aggressiveness and tendency to affect younger women compared to other breast cancer types.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Openalex Percentile: Top 14%
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.